title: Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved.
authors.affiliation: Institute of Neurology, Catholic University, Rome, Italy.
authors.forename: Assunta
authors.initials: A
authors.lastname: Bianco
authors.affiliation: Institute of Neurology, Catholic University, Rome, Italy.
authors.forename: Paolo Maria
authors.initials: PM
authors.lastname: Rossini
authors.affiliation: Institute of Neurology, Catholic University, Rome, Italy.
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Mirabella
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D057915:Drug Substitution / Q000379:methods*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011409:Propylene Glycols / Q000627:therapeutic use*; D013110:Sphingosine / Q000031:analogs & derivatives*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D013110:Sphingosine